Interesting data!
📊One-third of HER2+ eBC patients eligible for NAC had T2N0 disease and were ineligible for DB11. Anthracycline-free THP seems reasonable for this group.
⚖️For T3+ or N1+ disease, DB11 regimen or T(C)HP? Further treatment individualization is needed.
#ESMO26
136 views · 1 like · 1 repost · 0 replies
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.orgMoving beyond one-size fits all in HER2+ BC involves understanding trends. We explored a database of ~15.000 pts treated with neoadjuvant pertuzumab based NAT. We found that the T2N0 population (DB11-ineligible) is progressively expanding and has favorable 3y DRFS (96%) with SoC.在 X 查看被引用的帖子
Source: Yuhei YAMAGUCHI · x.com